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Atomoxetine and citalopram alter brain
network organization in Parkinson’s disease
Robin J. Borchert,1 Timothy Rittman,1 Charlotte L. Rae,2,3 Luca Passamonti,1,4
Simon P. Jones,1 Deniz Vatansever,5 Patricia Va´zquez Rodrı´guez,1 Zheng Ye,6
Cristina Nombela,7,8 Laura E. Hughes,1,9 Trevor W. Robbins10 and James B. Rowe1,9,10
Parkinson’s disease has multiple detrimental effects on motor and cognitive systems in the brain. In contrast to motor deficits, cog-
nitive impairments in Parkinson’s disease are usually not ameliorated, and can even be worsened, by dopaminergic treatments.
Recent evidence has shown potential benefits from restoring other neurotransmitter deficits, including noradrenergic and serotoner-
gic transmission. Here, we study global and regional brain network organization using task-free imaging (also known as resting-
state), which minimizes performance confounds and the bias towards predetermined networks. Thirty-three patients with idiopath-
ic Parkinson’s disease were studied three times in a double-blinded, placebo-controlled counter-balanced crossover design, follow-
ing placebo, 40mg oral atomoxetine (selective noradrenaline reuptake inhibitor) or 30mg oral citalopram (selective serotonin re-
uptake inhibitor). Neuropsychological assessments were performed outside the scanner. Seventy-six controls were scanned without
medication to provide normative data for comparison to the patient cohort. Graph theoretical analysis of task-free brain connectiv-
ity, with a random 500-node parcellation, was used to measure the effect of disease in placebo-treated state (versus unmedicated
controls) and pharmacological intervention (drug versus placebo). Relative to controls, patients on placebo had executive impair-
ments (reduced fluency and inhibitory control), which was reflected in dysfunctional network dynamics in terms of reduced cluster-
ing coefficient, hub degree and hub centrality. In patients, atomoxetine improved fluency in proportion to plasma concentration
(P¼ 0.006, r2¼ 0.24), and improved response inhibition in proportion to increased hub Eigen centrality (P¼ 0.044, r2¼ 0.14).
Citalopram did not improve fluency or inhibitory control, but its influence on network integration and efficiency depended on dis-
ease severity: clustering (P¼ 0.01, r2¼0.22), modularity (P¼ 0.043, r2¼0.14) and path length (P¼0.006, r2¼ 0.25) increased in
patients with milder forms of Parkinson’s disease, but decreased in patients with more advanced disease (Unified Parkinson’s
Disease Rating Scale motor subscale part III > 30). This study supports the use of task-free imaging of brain networks in transla-
tional pharmacology of neurodegenerative disorders. We propose that hub connectivity contributes to cognitive performance in
Parkinson’s disease, and that noradrenergic treatment strategies can partially restore the neural systems supporting executive
function.
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Introduction
Parkinson’s disease is characterized by its movement dis-
order but can also cause mild-to-severe cognitive deficits
which often involve impaired executive control.
Dopaminergic therapies have limited efficacy for the
treatment of cognitive changes in Parkinson’s disease and
may even worsen impulsivity (Cools et al., 2003; Voon
et al., 2006; Weintraub et al., 2006). To restore cognitive
function, an alternative approach is to target the deficits
in noradrenergic transmission (Williams-Gray et al.,
2007; Robbins and Arnsten, 2009; Vazey and Aston-
Jones, 2012; Kehagia et al., 2014; Ye et al., 2015) and
serotonergic transmission (Harrison et al., 1999; Fletcher
et al., 2007).
The primary source of forebrain noradrenaline is the
locus coeruleus nucleus in the brainstem (Aston-Jones
and Cohen, 2005), which is also an early site of path-
ology in Parkinson’s disease (Braak et al., 2003). This
suggests that the noradrenergic system is a potential tar-
get for therapeutic intervention. The drug atomoxetine is
a noradrenaline reuptake inhibitor which increases
noradrenaline levels in the prefrontal cortex (Bymaster
et al., 2002) and noradrenaline transporter occupancy
(Seneca et al., 2006). Atomoxetine facilitates attentional
set-shifting in preclinical studies (Newman et al., 2008)
and improves response inhibition in preclinical models
(Robinson et al., 2008) and healthy humans via modula-
tion of prefrontal cortex activity (Chamberlain et al.,
2009). In Parkinson’s disease, atomoxetine improves be-
havioural performance in a subgroup of patients, includ-
ing enhanced response inhibition in relation to increased
prefrontal cortex activity and fronto-striatal connectivity
(Kehagia et al., 2014; Ye et al., 2015; Rae et al., 2016).
Serotonin has also been implicated in the cognitive defi-
cits associated with Parkinson’s disease, and executive
functions mediated by the prefrontal cortex (Rubia et al.,
2005). The main source of forebrain serotonergic innerv-
ation is the raphe nuclei of the brainstem (Wilson and
Molliver, 1991). This is also an early site of neurodegen-
eration in Parkinson’s disease (Braak et al., 2003), which
impairs serotonergic transmission in the prefrontal cortex
(Politis et al., 2010). Restoring serotonergic innervation is
thus another potential target to improve the cognitive
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deficits in Parkinson’s disease. This notion is supported
by a study showing that the serotonin reuptake inhibitor,
citalopram, improves response inhibition in patients with
moderate-to-severe disease, in association with increased
prefrontal activation (Ye et al., 2014).
Previous psychopharmacological imaging studies have
assessed the effects of serotonin and noradrenaline re-
uptake inhibition on activity and connectivity during task
performance. However, task-free (also known as resting-
state) functional magnetic resonance imaging can be used
to examine the effect of a drug on widespread brain net-
work connectivity. Task-free functional magnetic reson-
ance imaging allows for the inclusion of more diverse
patients with significant cognitive and motor impairments
while also minimizing task-related confounds, training
demands and practice effects. It has been shown, for ex-
ample, that noradrenaline influences fluctuations in brain
network organization (van den Brink et al., 2016, 2018),
and atomoxetine enhances prefrontal cortical connectivity
in Parkinson’s disease in proportion to its effect on ver-
bal fluency, a marker of executive function (Borchert
et al., 2016).
The current study tested the hypotheses that the partial
restoration of noradrenergic and serotonergic levels in
Parkinson’s disease, via atomoxetine and citalopram re-
spectively, restores brain network organization. To ad-
dress this, we quantified the global and regional patterns
of network integration and segregation using graph theor-
etical measures and compared these to indices of cogni-
tive performance and disease severity. We tested two
principal hypotheses: (i) Parkinson’s disease impairs
whole-brain network function, quantified in terms of hub
connectivity, modularity and centrality; and (ii) treatment
by atomoxetine and citalopram restores these functional
brain network properties, in a subset of patients accord-
ing to severity and drug level.
Materials and methods
Participants
Thirty-three Parkinson’s disease patients were recruited
from the Cambridge University Parkinson’s disease
Research Clinic according to United Kingdom Parkinson’s
disease Society Brain Bank criteria. Seventy-six age- and
sex-matched controls were recruited from the healthy vol-
unteers registered with the Cambridge University
Parkinson’s disease Research Clinic and the Medical
Research Council’s Cognition and Brain Sciences Unit.
Inclusion criteria were (i) right-handed; (ii) age 45–
80 years; (iii) non-demented clinically and with Mini-
Mental State Examination score >26/30; (iv) no clinically
significant current depression; (v) no history of significant
psychiatric disorder or epilepsy; and (vi) no contraindica-
tions to magnetic resonance imaging, atomoxetine or cita-
lopram. None of the patients declared symptoms of
impulse control disorders. The study was approved by
the local research ethics committee with exemption from
clinical trials status by the United Kingdom Medicines for
Human Use Regulatory Agency. All participants provided
written consent.
Parkinson’s disease patients were administered the
Unified Parkinson’s Disease Rating Scale motor subscale
part III on each study day, and all participants under-
went cognitive assessment using the Mini-Mental State
Examination, digit span forward and backward, category
and letter fluency (Rittman et al., 2013), the revised
Beck-Depression Inventory and a stop-signal reaction time
task.
We anticipate that any potential future use of noradre-
nergic or serotonergic treatments targeting cognition in
Parkinson’s disease would be adjunctive, and not an al-
ternative, to standard dopaminergic therapy. Therefore,
the effect of these drugs on patients was assessed in the
context of their usual clinically optimized dopaminergic
medication. Patients were not taking other directly seroto-
nergic or noradrenergic medication, nor mono-amine-oxi-
dase inhibitors. Levodopa equivalent dose was estimated
(Tomlinson et al., 2010) and included as a covariate in
the analysis.
Experimental design
A randomized double-blinded, placebo-controlled cross-
over design was used for patient treatment by atomoxe-
tine, citalopram and placebo. Patients underwent three
separate sessions, at least 6 days apart at approximately
the same time of day, consisting of cognitive and neuro-
logical assessments and brain imaging. The drug order
was counter-balanced using permutation within groups of
six successive subjects to reduce session-order effects on
the drug effect. One patient participated in the control
and atomoxetine sessions but not the citalopram session.
Each patient received a 40mg oral dose of atomoxetine,
a 30mg oral dose of citalopram or a placebo capsule at
the start of each session. Drug plasma concentrations
were measured and patients were scanned 2 h after ad-
ministration to coincide with peak plasma concentration
for atomoxetine (Sauer et al., 2005) and citalopram
(Sangkuhl et al., 2011). Controls were scanned once
without drug or placebo to provide normative data. Note
that the effect of disease (patient on placebo versus con-
trol) is confounded by potential placebo effects. The prin-
cipal analysis of interest was the main effect of drug
treatment within the patient group.
Functional magnetic resonance
imaging data acquisition and
pre-processing
Task-free functional imaging was performed at rest using
a TIM-Trio 3T magnetic resonance imaging scanner
(Siemens Medical Systems, Erlangen, Germany). A
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minimum of 145 volumes were acquired using an echo-
planar imaging sequence (repetition time 2000ms, echo
time 30ms, matrix¼ 64 64, in-plane resolution of
3 3mm, 32 slices of 3mm thickness with a 0.75mm
interslice gap, and a flip angle of 78). Structural
Magnetization-Prepared Rapid Acquisition with Gradient
Echo scans (repetition time of 2300ms, echo time
2.86ms, matrix¼ 192 192, in-plane resolution of
1.25 1.25mm, 144 slices of 1.25mm thickness, inver-
sion time of 900ms and flip angle of 9) were also
acquired during the same session.
In order to account for atrophy and in-scanner head
movements, a pre-processing pipeline optimized for older
subjects was used (Patel et al., 2014). We used a study-
specific template generated from the Magnetization-
Prepared Rapid Acquisition with Gradient Echo images
using the Diffeomorphic Anatomical Registration
Through Exponentiated Lie Algebra algorithm
(Ashburner, 2007). Structural images were segmented and
grey and white matter images from all participants were
iteratively warped together over six steps to create the
study-specific template which was then affine transformed
to Montreal Neurological Institute (MNI) space.
Functional images were pre-processed using a custom-
ized version of the brainwavelet toolbox. Pre-processing
steps included removal of the first five volumes, coregis-
tration of the mean echo-planar imaging image to the T1
image, transformation of the coregistered echo-planar
imaging to MNI space using the flow fields generated by
the Diffeomorphic Anatomical Registration Through
Exponentiated Lie Algebra algorithm, slice-timing correc-
tion, combined regression of cerebrospinal fluid signal
and motion derivatives, high-pass band filter (0.01Hz)
and wavelet despiking (Patel et al., 2014).
We combined approaches to minimize in-scanner head
movement-related effects on the blood oxygenation level
dependent signal. Wavelet despiking was used to despike
movement-related non-stationary events on a voxel level.
Participants were excluded based on the average root
mean-squared displacement computed from the transla-
tion parameters of head motion: average root mean-
squared displacement over two standard deviations (SD)
from the mean and/or 2 SDs from the mean difference
between placebo and drug sessions for patients.
Graph analysis
Graph theoretical analysis was used to investigate the
characteristics of brain network organization. In the con-
text of the brain, networks are composed of nodes,
which represent brain regions, and edges, which represent
the connectivity between the regions. Nodes were identi-
fied using a random 500-node parcellation to create
nodes of approximately equal size. Nodes that were not
sufficiently covered in ten participants or more were
excluded (n¼ 27). Wavelet correlations were used to gen-
erate association matrices (Achard et al., 2006). To
generate binary graphs, local thresholds were applied
(Alexander-Bloch et al., 2010) with thresholds between
1% and 10%. An intermediate density of 6% was used
for primary statistical analysis (Cope et al., 2018). The
graphs were Fisher-z transformed to normalize the correl-
ation coefficients. A correction for multiple comparisons
was not applied as network measures are not independ-
ent (Rittman et al., 2019).
The Maybrain toolbox (https://github.com/
RittmanResearch/maybrain) was used to compute the
three main topological properties of the networks using
the correlation matrices: (i) Path length is the average
shortest path length in a network and provides a measure
of the efficiency of network-wide communication. (ii)
Clustering coefficient is a measure of the extent to which
a node’s neighbours are inter-connected and provides in-
sight into the local efficiency of a network. The organiza-
tion of functional connectivity in the brain is similar to
that of a small-world network which is characterized by
low path length and high clustering coefficient, creating
an efficient network architecture with low connection
cost (Latora and Marchiori, 2003). (iii) Modularity
reflects the functional divisions of brain networks into
clusters which are densely intra-connected and more
sparsely inter-connected.
Hub metrics
Hubs are highly connected nodes and their function is
vital for information processing in a small-world network
(Heuvel and Sporns, 2013; Stam, 2014). The functional
significance of these hubs was quantified by computing
the number of nodes connected to the hub node (degree)
and the extent to which the hub node is central to infor-
mation processing within the network. Hub regions were
defined as nodes with a connection strength over 1.5 SDs
above the mean in a randomly selected cohort consisting
of half of the control participants (n¼ 37). These nodes
were used to compare hub metrics (degree, closeness cen-
trality, betweenness centrality, Eigen centrality) in the
other half of the controls, not used for hub identification
(n¼ 38), to the patient placebo group (n¼ 30). Hub met-
rics were then compared in patients between no drug and
drug sessions to determine if atomoxetine and/or citalo-
pram modulated hub connectivity.
Statistical analysis
Normative brain network graph metrics were quantified
and compared between controls and the patient placebo
group, using two-sample t-tests. Outlier participants be-
yond 2 SDs from the mean were removed prior to ana-
lysis. The effect of drug on network connectivity was
investigated using a repeated-measures ANOVA for graph
measures in patients. Measures of age, Unified
Parkinson’s Disease Rating Scale motor subscale part III,
levodopa equivalent dose (Tomlinson et al., 2010),
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change in neuropsychological performance on drug versus
no drug and drug plasma concentration were included as
covariates to investigate interactions between patient
demographic/clinical characteristics and the effects of
atomoxetine and citalopram on network connectivity.
Data availability
The terms of original participant consent prevent Open
Access to raw data or other personally identifiable data
but we would welcome requests from potential academic
collaborators (please contact the senior author), while
summary data and derived images may be requested
from the corresponding author.
Results
After exclusions, the data from 75 controls and 30
patients (atomoxetine condition: n¼ 30, citalopram condi-
tion n¼ 29) were carried forward for analysis. Patient
demographic and neuropsychological information are
shown in Table 1. Controls and patients were matched
for sex, age and education. Relative to controls, patients
had lower Mini-Mental State Examination and category
fluency scores and longer stop-signal reaction times as
expected.
Eleven nodes in the graph had a degree over 1.5 SDs
from the mean in the randomly selected control cohort
(n¼ 37) and were designated as hub nodes. The regions
of these hub nodes are listed in Table 2, with numerical
labelling according to the automated anatomical labelling
atlas.
Controls versus patients on placebo
There was no significant difference in path length or
modularity between controls and patients on placebo.
However, patients on placebo had lower clustering
coefficient (P¼ 0.038), hub degree (P¼ 0.0001), hub
betweenness centrality (P¼ 0.009), hub closeness central-
ity (P¼ 0.032) and hub Eigen centrality (P¼ 0.02).
Effect of atomoxetine in patients
Within the patient group, peak plasma concentration of
atomoxetine correlated with change in category fluency
on the drug; patients with higher plasma concentrations
demonstrated greater improvement (P¼ 0.006, r2¼ 0.24;
Fig. 1).
There was no significant main effect of atomoxetine on
global clustering coefficient, path length, or modularity,
relative to placebo. There was also no interaction be-
tween the effect of atomoxetine on these global graph
metrics and covariates of interest. Lower baseline hub
metrics correlated with a greater increase in the respective
metric with atomoxetine towards controls for hub betwe-
enness centrality (P¼ 0.022, r2¼ 0.17), hub closeness cen-
trality (P< 0.0005, r2¼ 0.47) and hub Eigen centrality
(P¼ 0.01, r2¼ 0.21). Behavioural inhibition on a stop-sig-
nal task improved in patients on atomoxetine in propor-
tion to baseline Eigen centrality (P¼ 0.025, r2¼ 0.17)
and increased hub Eigen centrality on the drug
(P¼ 0.044, r2¼ 0.14) (Fig. 2).
Effect of citalopram in patients
Citalopram did not change fluency or inhibitory control
at the group level or in proportion to plasma concentra-
tion. Lower baseline graph metrics correlated with a
greater increase on citalopram towards controls in the re-
spective metric for clustering coefficient (P¼ 0.031,
r2¼ 0.16), modularity (P¼ 0.036, r2¼ 0.15), hub degree
(P< 0.0005, r2¼ 0.59), hub betweenness centrality
(P< 0.0005, r2¼ 0.76) and hub closeness centrality
(P< 0.0005, r2¼ 0.57). Citalopram decreased clustering
coefficient (P¼ 0.01, r2¼ 0.22), path length (P¼ 0.006,
r2¼ 0.25) and modularity (P¼ 0.043, r2¼ 0.14; Fig. 3) in
Table 1 Participant clinical, cognitive and demographic characteristics at baseline before trial medication
Patients mean (SD) Controls mean (SD) Difference
(P-value)
Male:female 19:11 41:34 ns
Age (years) 67 (7.3) 67.1 (8.4) ns
Education (years) 14.2 (3.6) 14.8 (4.0) ns
Mini-Mental State Examination 28.4 (1.7) 29.2 (1.1) 0.009
Disease duration (years) 10.5 (4.4)
Levodopa equivalent dose (mg/day) 870 (469)
Unified Parkinson’s Disease Rating Scale motor subscale part III ‘on’ 22.6 (6.8)
Category fluency 18.3 (5.5) 24.3 (6.2) 0.0001
Letter fluency 16.0 (4.4) 18.3 (5.7) ns
Digit span forward 7.0 (1.1) 7.3 (0.8) ns
Digit span backward 5.5 (1.2) 6.0 (1.3) ns
Stop-signal reaction time (ms) 198 (73) 164 (39) 0.02
Atomoxetine plasma concentration (ng/ml) 372.1 (167.4)
Citalopram plasma concentration (ng/ml) 35.6 (14.7)
Groups are compared by unpaired t-test or chi-squared test as appropriate.
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proportion to disease severity (higher Unified Parkinson’s
Disease Rating Scale motor subscale part III scores).
Citalopram did not alter group-wise global or hub metrics.
Discussion
This study reinforces the potential for noradrenergic re-
uptake inhibition (by atomoxetine) to improve brain net-
work function in Parkinson’s disease, aimed at improving
executive function. The potential for a serotonergic thera-
peutic effect depends on the severity of disease, as meas-
ured clinically by the Unified Parkinson’s Disease Rating
Scale motor subscale part III. These drug effects are set
in the context of the impact of Parkinson’s disease on
brain network function including the reduction of hub
connectivity, and network modularity and centrality.
The task-free functional magnetic resonance imaging
encompassed both motor and cognitive networks.
Although the loss of task-specificity may be seen as a dis-
advantage, the task-free approach has many advantages,
including the minimization of performance confounds and
practice effects in crossover designs; the scalability across
severity levels, sites and languages in multicentre studies;
and quantification of connectivity in nodes across several
networks. It has revealed commonalities across many de-
generative disorders in terms of network reorganization
and hub connectivity in particular (Crossley et al., 2014).
This makes it well suited to study a heterogeneous dis-
order such as Parkinson’s disease, with its motor and
cognitive impairments (Williams-Gray et al., 2013;
Yarnall et al., 2014).
In addition to the intrinsic heterogeneity of Parkinson’s
disease, an oral dose of drug leads to widely differing
plasma levels between individuals (Ye et al., 2015). This
means that a single dose may not be equally effective in
all patients and simple group-wise comparisons are likely
to produce null findings. This is also true for dopamin-
ergic effects on non-motor functions (Rowe et al., 2008;
Cools et al., 2009) but it places particular emphasis on
the need for predictive models of response, or at least
stratification tools for future clinical trials. In this ex-
ploratory study however, we sought to explain changes
in the effect of drug in relation to drug levels and disease
severity.
For atomoxetine, the change in fluency correlated with
drug plasma concentration. Previous authors have
suggested the relationship between atomoxetine concen-
tration and task performance follows a Yerkes-Dodson
Table 2 Hub node regions used for analysis
Automated
Anatomical Labeling
atlas numerical label
Automated Anatomical
Labeling atlas region
10 Right middle frontal gyrus, orbital part
16 Right inferior frontal gyrus, pars orbitalis
34 Right midcingulate area
55 Left fusiform gyrus
78 Right thalamus
81 Left superior temporal gyrus
83 Left superior temporal pole
84 Right superior temporal pole
90 Right inferior temporal gyrus
91 Left crus I of cerebellar hemisphere
100 Right lobule VI of cerebellar hemisphere
Figure 1 Atomoxetine plasma concentrations. Patients with
higher peak plasma concentrations of atomoxetine demonstrated
greater improvement in category fluency (measured by number of
words produced in a category) on the drug relative to placebo
(P¼ 0.006, r2¼ 0.24).
Figure 2 Hub centrality on atomoxetine. Patients with
increased hub Eigen centrality on atomoxetine had faster stop-
signal reaction times (ms) on the drug (P¼ 0.044, r2¼ 0.14).
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‘inverted U-shaped’ function (Aston-Jones and Cohen,
2005; Bari and Aston-Jones, 2013) which is influenced
by baseline noradrenergic levels. For example, an individ-
ual with relatively higher baseline noradrenergic levels
may overshoot the range for optimal performance if
treated with atomoxetine (Housden et al., 2011).
Atomoxetine administration in mild disease with pre-
sumed relatively intact endogenous noradrenaline systems
was detrimental, indicative of an ‘overdose’, placing nor-
adrenaline beyond its optimal range (Ye et al., 2015).
Here, we examined the effect of atomoxetine on verbal
fluency, as both a marker of executive function and as a
significant predictor of cognitive decline (Williams-Gray
et al., 2007). Atomoxetine plasma concentration and the
change in fluency were correlated. A similar linear rela-
tionship was identified between atomoxetine plasma con-
centration and improvement on a task of problem-solving
and working memory (Kehagia et al., 2014). We did not
observe a direct relationship between atomoxetine plasma
concentration and inhibitory control (the stop-signal reac-
tion time task). However, there was an indirect relation-
ship, expressed in terms of the effect of atomoxetine on
hub Eigen centrality and the effect of atomoxetine on in-
hibitory control. The effects of atomoxetine on different
cognitive domains may be a feature of their different nor-
adrenergic ‘optima’ or the differential degrees of neurode-
generation in neural circuits serving each cognitive
domain (Haber, 2003; Rowe et al., 2008; Rowe and
Rittman, 2016). In addition to plasma concentration, dis-
ease severity and the extent of noradrenergic denervation
also influence response to atomoxetine in these patients.
Noradrenaline is significantly reduced in the brain of
Parkinson’s disease patients (Goldstein et al., 2014) and
correlates with motor disease severity (Marie´ et al.,
1995). Previous work has demonstrated that the effect of
atomoxetine on fronto-striatal effective connectivity (Rae
Figure 3 Network connectivity on citalopram. Citalopram decreased (A) clustering coefficient (P¼ 0.01, r2 ¼ 0.22), (B) path length
(P¼ 0.006, r2¼ 0.25) and (C) modularity (P¼ 0.043, r2¼ 0.14) in Parkinson’s disease patients with higher Unified Parkinson’s Disease Rating
Scale motor subscale part III scores.
Brain networks in Parkinson’s disease BRAIN COMMUNICATIONS 2019: Page 7 of 10 | 7
et al., 2016) and stop-related inferior frontal gyrus activa-
tion (Ye et al., 2015) depends on disease severity. Hence,
we suggest that both plasma concentration and noradre-
nergic denervation, indexed by disease severity, contribute
to drug response in these patients.
Considering the widespread noradrenergic and seroto-
nergic projections which are compromised in Parkinson’s
disease, we predicted an effect of atomoxetine and citalo-
pram on global network topology. Highly connected hub
regions are preferentially affected in Parkinson’s disease,
as well as other neurodegenerative diseases (Crossley
et al., 2014), and loss of hub connectivity, particularly in
the prefrontal cortex, has been linked to executive dys-
function (Rittman et al., 2016). Although atomoxetine
did not significantly alter whole-brain graph measures, it
did change hub connectivity. Patients with increased hub
Eigen centrality on atomoxetine demonstrated improved
inhibitory control in terms of the stop-signal task per-
formance recorded outside the scanner. These improve-
ments in behavioural inhibition and hub Eigen centrality
on atomoxetine were seen in patients with lower baseline
hub Eigen centrality on placebo. The stop-signal task elic-
its activation of the prefrontal cortex, particularly the
right inferior frontal gyrus and pre-supplementary motor
area (Garavan et al., 1999; Aron et al., 2003; Rubia
et al., 2003; Eagle et al., 2008; Rae et al., 2015).
Improved inhibitory control following atomoxetine ad-
ministration is mediated by inferior frontal gyrus activity
and its connectivity through the basal ganglia in
Parkinson’s disease (Ye et al., 2015; Borchert et al.,
2016; Rae et al., 2016) and healthy adults (Chamberlain
et al., 2009). In our study, the change in connectivity of
hubs correlated with improved stop-signal reaction time
task on atomoxetine: these hub regions overlapped with
those known to associate with response inhibition.
Previous studies of citalopram in healthy volunteers
found reduced task-free functional connectivity following
drug administration (McCabe and Mishor, 2011;
Schaefer et al., 2014; Klaassens et al., 2017). In the con-
text of depression, these authors hypothesized that citalo-
pram acted by normalizing functional connectivity. In
Parkinson’s disease there is also a disruption of seroto-
nergic transmission (Politis and Niccolini, 2015) which
progresses over time (Politis et al., 2010), including
regions of prefrontal cortex that are closely associated
with inhibitory control, learning and cognitive flexibility,
not only affective cognition. For example, the behavioural
effects of serotonergic manipulations on response inhib-
ition are mediated by the prefrontal cortex (Del-Ben
et al., 2005; Macoveanu et al., 2013). Here, we found
that improved clustering coefficient, modularity and hub
connectivity on citalopram were associated with lower
baseline values for these metrics. However, these meas-
ures were not associated with any change in cognitive
performance on the drug. We previously reported that
the benefit of citalopram on response inhibition and an
associated neural activation emerged only in patients with
more advanced disease, especially if they had relatively
preserved fronto-striatal connectivity (Ye et al., 2014). In
the current analysis, the effect of Parkinson’s disease was
to reduce the brain’s clustering coefficient and centrality
measures. If this were primarily due to serotonergic
impairments, we would expect that citalopram would in-
crease these network properties towards a normal level
with more severe disease. However, despite a modest
positive effect on connectivity in patients with mild dis-
ease, this effect declined with disease severity. In other
words, patients with more severe disease appeared resist-
ant to the effect of citalopram on the topology of brain
network organization. This was unexpected and could be
the result of altered response to citalopram due to signifi-
cant degeneration in the more severely affected patients.
Serotonergic transmission is disrupted in Parkinson’s dis-
ease and the extent of denervation progresses with dis-
ease severity (Politis et al., 2010; Politis and Niccolini,
2015). An impaired serotonergic architecture could ex-
plain the resilience of global and hub metrics to citalo-
pram in more advanced disease. We speculate that our
findings result from the heterogeneity of the effects of
Parkinson’s disease and variable sites of action of citalo-
pram, leading to a null effect on global measures in
patients with severe disease, in contrast to the previously
reported effects on focal prefrontal cortical activations
(Ye et al., 2014). Future investigations using 7T-magnetic
resonance imaging of the locus coeruleus (Betts et al.,
2019), PET imaging of serotonergic receptor density or
noradrenaline transporter density, or dopamine transport-
er imaging using single-photon emission computed tomog-
raphy, could provide further insight into the relationship
between drug response and the integrity of noradrenergic,
dopaminergic and serotonergic systems.
This study had several limitations. First, although
patients received one dose of atomoxetine or citalopram
during brain imaging, chronic drug administration may
differentially affect cognitive and functional connectivity
(Koda et al., 2010). This could be mediated by down-
regulation of neurotransmitter receptors or synthesis and
future studies should investigate the effect of chronic
drug treatment. Second, blood oxygenation level depend-
ent signals could have been influenced by atomoxetine,
citalopram and/or dopaminergic drugs. However, this is
unlikely as cerebral blood flow remains normal following
atomoxetine (Marquand et al., 2012) and citalopram
(Macoveanu et al., 2013) administration, and dopamin-
ergic therapy was kept constant in the within-subject
crossover analyses. Although the non-trial medication
was kept constant as part of patients’ standard therapy
in the drug versus placebo comparison, this was not con-
trolled for when comparing patients on placebo to
healthy controls. Indirect effects of placebo treatment on
cognitive or neurotransmitter systems confound the com-
parison of patients with controls in this study. However,
this caveat does not affect the comparison of drug versus
placebo in patients. Third, the mediating effect of
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atomoxetine on functional connectivity has several poten-
tial contributory mechanisms. Atomoxetine can affect
dopaminergic as well as noradrenergic transmission
(Bymaster et al., 2002). However, effects of atomoxetine
on response inhibition have been shown to be primarily
mediated by noradrenergic transmission in animal studies
(Bari et al., 2009).
In conclusion, atomoxetine and citalopram modulate
resting-state functional connectivity in Parkinson’s disease
in different ways. We suggest that hub connectivity medi-
ates the effect of atomoxetine on executive function while
citalopram alters whole-brain graph metrics according to
disease severity. This study provides support for the use
of task-free imaging methods to assess the impact of
drugs on neurocognitive systems in patients.
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